Peptide Reports

CJC-1295 with DAC Peptide Report

Peptide Report

CJC-1295 with DAC Peptide Report

Catalog report for CJC-1295 with DAC, generated from Peptide Stacks product data and linked to the matching PeptideReports protocol page when available.

All peptide reportsProtocol library
Current Price$85.00 CAD
ProtocolCJC-1295 with DAC protocol
Catalog SourceBuy Product

Available Options

  • 5 MG

Common Uses

People commonly discuss CJC-1295 with DAC for longer-acting growth-hormone support routines tied to recovery, sleep quality, body composition, and general performance habits.

How It Works

CJC-1295 with DAC is a GHRH analog designed with a drug-affinity-complex extension. The DAC portion binds albumin and extends exposure time, while the peptide portion stimulates pituitary GHRH receptors to support growth-hormone release.

Storage

Powder form: In lyophilized powder form, CJC-1295 with DAC is generally kept sealed, dry, protected from direct light, and refrigerated unless the product label or certificate of analysis gives different handling instructions. Avoid leaving vials in hot rooms, vehicles, direct sunlight, or other temperature swings, because moisture, heat, and light are the main storage conditions people try to control before reconstitution.

Reconstituted: After reconstitution, CJC-1295 with DAC should generally be treated as more sensitive: keep it refrigerated, minimize unnecessary handling, avoid shaking, and use clean handling practices each time the vial is accessed. Follow the product label, protocol page, and any pharmacy or lab guidance for beyond-use timing; if the solution changes color, becomes cloudy, develops particles, or the vial integrity is questionable, it should not be used.

Protocol

The full CJC-1295 with DAC protocol is included below. The standalone protocol page remains available if you want to open it separately.

Open Standalone Protocol

Scope

Preparation examples, syringe conversion, community-reported patterns and important limitations.

Available strengths: 5 MG

Preparation Examples

These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.

Setup Diluent Concentration Unit conversion
5 MG vial – 2 mL example Add 2 mL bacteriostatic water 2.5 mg/mL Each U-100 unit = 25 mcg
5 MG vial – 1 mL example Add 1 mL bacteriostatic water 5 mg/mL Each U-100 unit = 50 mcg

Syringe Conversion

Reported amount 5 MG setup 5 MG setup
500 mcg 20 units 10 units
1 mg 40 units 20 units
2 mg 80 units 40 units
3 mg 120 units 60 units

Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.

Community-Reported Patterns

Recurring report Frequency seen Context in reports
500 mcg Once or twice weekly Lower-start reports
1-2 mg Once weekly Most recurring range
2 mg Twice weekly in some reports Higher experimental use

Observations

  • Community discussions most often centered on sleep, recovery and body-composition goals.
  • The amount, frequency, route and cycle length varied substantially between reports.
  • Reported outcomes were commonly confounded by diet, training, other products or existing treatment.

Caveats

  • The DAC form has prolonged activity and is not interchangeable with CJC-1295 no DAC; frequency mistakes can materially change exposure.
  • Community reports are uncontrolled anecdotes and do not establish an appropriate dose, safety, product identity, purity or efficacy.

Sources

  1. Community search: CJC-1295 with DAC
  2. PubMed literature search: CJC-1295 with DAC